BIOMARIN PHARMACEUTICAL INC (BMRN) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $194.00K; Additional Paid in Capital, Common StockUSD $6.04B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-8.78M; Retained Earnings (Accumulated Deficit)USD $304.50M.
- 2026-03-31: Common Stock, Value, IssuedUSD $193.00K; Additional Paid in Capital, Common StockUSD $5.97B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-4.24M; Retained Earnings (Accumulated Deficit)USD $259.73M.
- 2025-12-31: Common Stock, Value, IssuedUSD $192.00K; Additional Paid in Capital, Common StockUSD $5.96B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-13.47M; Retained Earnings (Accumulated Deficit)USD $154.21M.
- 2025-09-30: Common Stock, Value, IssuedUSD $192.00K; Additional Paid in Capital, Common StockUSD $5.90B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-33.94M; Retained Earnings (Accumulated Deficit)USD $200.78M.
BIOMARIN PHARMACEUTICAL INC Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Other USD | AOCI Including Portion Attributable to Noncontrolling Interest, before Tax USD | Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax USD | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $194.00K | $6.04B | $-8.78M | $304.50M | $6.32B | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $193.00K | $5.97B | $-4.24M | $259.73M | $6.21B | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $192.00K | $5.96B | $-13.47M | $154.21M | $6.09B | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $192.00K | $5.90B | $-33.94M | $200.78M | $6.06B | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $192.00K | $5.85B | $-44.56M | $231.52M | $6.03B | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $192.00K | $5.79B | $19.15M | $-9.01M | $5.79B | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $191.00K | $5.80B | $61.65M | $-194.69M | $5.66B | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $191.00K | $5.74B | $4.65M | $-319.64M | $5.41B | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $190.00K | $5.70B | $26.80M | $-425.72M | $5.29B | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $190.00K | $5.62B | $-1.05M | $-532.89M | $5.07B | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $189.00K | $5.61B | $-28.79M | $-621.55M | $4.95B | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $188.00K | $5.54B | $6.26M | $-641.93M | $4.90B | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $188.00K | $5.49B | $-18.62M | $-682.31M | $4.78B | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $188.00K | $5.42B | $-10.72M | $-738.35M | $4.66B | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $186.00K | $5.40B | $-3.87M | $-789.20M | $4.60B | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $186.00K | $5.34B | $30.75M | $-788.95M | $4.57B | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $186.00K | $5.27B | $18.47M | $-777.23M | $4.50B | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $185.00K | $5.21B | $-877.00K | $-804.89M | $4.39B | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $184.00K | $5.19B | $14.43M | $-930.76M | $4.27B | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $184.00K | $5.13B | $10.24M | $-867.79M | $4.26B | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $183.00K | $5.08B | $-939.00K | $-831.30M | $4.24B | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $183.00K | $5.01B | $5.00M | $-844.24M | $4.16B | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $182.00K | $4.99B | $-16.14M | $-861.61M | $4.10B | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $181.00K | $4.94B | $10.38M | $-883.71M | $4.05B | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $181.00K | $4.89B | $30.05M | $-1.67B | $3.24B | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $181.00K | $4.85B | $34.13M | $-1.64B | $3.24B | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $180.00K | $4.83B | $20.16M | $-1.72B | $3.12B | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $180.00K | $4.78B | $37.00M | $-1.74B | $3.07B | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $179.00K | $4.74B | $17.44M | $-1.79B | $2.96B | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $179.00K | $4.68B | $19.79M | $-1.75B | $2.94B | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $178.00K | $4.67B | $5.27M | $-1.69B | $2.97B | 12 month · $155.14M | (m) | (m) | (m) | (m) |
| 2018-09-30 | $178.00K | $4.62B | $-2.16M | $-1.69B | $2.91B | 9 month · $116.14M | (m) | (m) | (m) | (m) |
| 2018-06-30 | $178.00K | $4.58B | $-1.13M | $-1.68B | $2.89B | 6 month · $77.77M | (m) | (m) | (m) | (m) |
| 2018-03-31 | $177.00K | $4.51B | $-28.55M | $-1.66B | $2.81B | 3 month · $37.00M | (m) | (m) | (m) | (m) |
| 2017-12-31 | $176.00K | $4.48B | $-22.96M | $-1.64B | $2.81B | 12 month · $145.28M | (m) | (m) | (m) | (m) |
| 2017-09-30 | $176.00K | $4.44B | $-21.43M | $-1.59B | $2.81B | 9 month · $110.61M | (m) | (m) | (m) | (m) |
| 2017-06-30 | $175.00K | $4.40B | $-14.66M | $-1.57B | $2.80B | 6 month · $73.36M | (m) | (m) | (m) | (m) |
| 2017-03-31 | $173.00K | $4.31B | $5.02M | $-1.54B | $2.77B | 3 month · $31.52M | (m) | (m) | (m) | (m) |
| 2016-12-31 | $173.00K | $4.29B | $12.82M | $-1.52B | $2.77B | 12 month · $136.66M | (m) | (m) | (m) | (m) |
| 2016-09-30 | $173.00K | $4.23B | $2.16M | $-1.57B | $2.65B | 9 month · $100.01M | (m) | (m) | (m) | 9 month · $563.00K |
| 2016-06-30 | $164.00K | $3.46B | $4.53M | $-1.53B | $1.92B | 6 month · $65.84M | (m) | (m) | 3 month · $2.22M 6 month · $-5.40M | 6 month · $314.00K |
| 2016-03-31 | $163.00K | $3.41B | $47.00K | $-1.11B | $2.29B | 3 month · $31.02M | (m) | (m) | 3 month · $7.62M | 3 month · $99.00K |
| 2015-12-31 | $162.00K | $3.41B | $21.03M | $-1.02B | $2.40B | 12 month · $115.49M | (m) | (m) | 12 month · $20.80M | 12 month · $2.19M |
| 2015-09-30 | $162.00K | $3.37B | $25.18M | $-1.09B | $2.29B | (m) | (m) | $30.92M | (m) | (m) |
| 2015-06-30 | $161.00K | $3.34B | $32.46M | $-999.26M | $2.36B | (m) | (m) | $41.16M | 3 month · $-8.18M 6 month · $-12.92M | (m) |
| 2015-03-31 | $161.00K | $3.31B | $43.82M | $-917.27M | $2.43B | (m) | (m) | $54.50M | 3 month · $4.74M | (m) |
| 2014-12-31 | $149.00K | $2.36B | $27.47M | $-849.77M | $1.53B | 12 month · $88.23M | (m) | $33.98M | 12 month · $643.00K | 12 month · $1.49M |
| 2014-09-30 | $148.00K | $2.28B | $19.19M | $-779.97M | $1.51B | (m) | (m) | $29.96M | (m) | (m) |
| 2014-06-30 | $147.00K | $2.25B | $9.94M | $-787.42M | $1.46B | (m) | (m) | $15.49M | (m) | (m) |
| 2014-03-31 | $146.00K | $2.21B | $7.28M | $-753.92M | $1.46B | (m) | (m) | $11.30M | (m) | (m) |
| 2013-12-31 | $144.00K | $2.06B | $5.02M | $-715.80M | $1.34B | 12 month · $66.18M | 12 month · $-19.07M | $7.76M | 12 month · $50.00K | 12 month · $733.00K |
| 2013-09-30 | $142.00K | $1.93B | $11.47M | $-653.81M | $1.28B | (m) | (m) | $16.98M | 9 month · $619.00K | (m) |
| 2013-06-30 | $140.00K | $1.86B | $2.44M | $-600.79M | $1.26B | (m) | (m) | $3.80M | 6 month · $554.00K | (m) |
| 2013-03-31 | $139.00K | $1.83B | $1.16M | $-579.26M | $1.25B | (m) | (m) | $1.82M | (m) | (m) |
| 2012-12-31 | $126.00K | $1.56B | $-202.00K | $-539.45M | $1.02B | 12 month · $47.34M | (m) | $-182.00K | (m) | 12 month · $473.00K |
| 2012-09-30 | $124.00K | $1.51B | $2.33M | $-486.44M | $1.02B | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | $123.00K | $1.48B | $4.65M | $-481.08M | $1.00B | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | $116.00K | $1.22B | $2.51M | $-449.07M | $771.95M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $115.00K | $1.20B | $4.89M | $-425.10M | $773.05M | 12 month · $43.91M | (m) | (m) | (m) | 12 month · $415.00K |
| 2011-09-30 | $114.00K | $1.18B | $1.30M | $-398.37M | $774.54M | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | $112.00K | $1.12B | $-5.92M | $-380.71M | $732.30M | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | $111.00K | $1.10B | $-5.79M | $-375.64M | $720.84M | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $111.00K | $1.09B | $188.00K | $-371.26M | $717.26M | 12 month · $38.36M | (m) | (m) | (m) | 12 month · $541.00K |
| 2010-09-30 | $103.00K | $948.39M | $-1.58M | $-359.08M | $585.66M | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | $102.00K | $931.36M | $10.22M | $-576.41M | $362.96M | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $101.00K | $899.95M | $933.00K | $-577.08M | $322.19M | 12 month · $36.01M | (m) | (m) | (m) | 12 month · $113.00K |
| 2008-12-31 | (m) | (m) | (m) | (m) | $276.68M | 12 month · $28.34M | (m) | (m) | (m) | 12 month · $960.00K |
| 2007-12-31 | (m) | (m) | (m) | (m) | $187.73M | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |